Related Experiment Videos
Hormone replacement and the prevention of cardiovascular disease
1University of California at San Diego, School of Medicine, La Jolla, California 92037, USA.
Insights
Hormone replacement therapy (HRT) shows conflicting cardiovascular protection results in postmenopausal women. Different formulations impact risk markers, requiring careful consideration for individual treatment decisions.
Area of Science:
- Cardiovascular Health
- Endocrinology
- Women's Health
Background:
- Conflicting evidence exists regarding hormone replacement therapy (HRT) for cardiovascular protection in postmenopausal women.
- Observational studies suggest HRT benefits primary prevention of cardiovascular disease (CVD), but controlled trials show no effect on CVD events or angiographic progression.
Purpose of the Study:
- To review the current evidence on HRT for cardiovascular protection in postmenopausal women.
- To discuss the impact of different HRT formulations on cardiovascular risk markers.
Main Methods:
- Review of observational studies and controlled trials on HRT and cardiovascular outcomes.
- Analysis of the effects of various estrogen and progestin combinations on cardiovascular risk markers.
Main Results:
- Observational studies indicate HRT may benefit primary CVD prevention.
- Controlled trials with estrogen plus progestin showed no effect on CVD events in older women with existing CVD.
- Estrogen-alone therapy in a primary prevention trial reduced carotid atheroma in high-risk patients.
Conclusions:
- Different HRT formulations have varying effects on cardiovascular risk markers.
- Individualized decision-making is crucial when considering HRT for cardiovascular protection, taking into account specific formulations and patient risk factors.
Abstract:
Recently, there has been considerable discussion about the benefits and risks of using hormone replacement therapy (HRT) for cardiovascular protection in postmenopausal women. Numerous studies have addressed this issue, with conflicting results. Observational studies strongly suggest a benefit of HRT for primary prevention of cardiovascular disease (CVD), whereas controlled trials that tested a single common regimen of estrogen plus progestin found no effect on CVD events or angiographic progression in older women with established CVD. More recently a primary prevention trial in high risk patients found reduced carotid atheroma with estrogen alone. A variety of combination therapies with various estrogens and progestins are now available. These formulations have significantly different effects on cardiovascular risk markers, which independently affect outcomes. This information should be considered when deciding whether to use HRT in an individual woman, and if so, which formulation to use.